Interestingly, a marked decrease in Nr4a1 was associated with a variety of neurological conditions, including Alzheimer’s and Parkinson’s diseases, schizophrenia and bipolar disorders, and various activators and modulators of this TF have been investigated as probable therapeutic drugs in neuroinflammatory and neuronal cell death models [92,93,94,95,96,97,98,99,100,101]. This evidence concerns the gene TF and Parkinson disease.